Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
about
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolatesPosaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicansSound waves effectively assist tobramycin in elimination of Pseudomonas aeruginosa biofilms in vitro.Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectivesAntifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformansDosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.Antifungal activity of Cymbopogon winterianus jowitt ex bor against Candida albicansCaspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration.Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms
P2860
Q28345261-1CDACB88-056B-490E-A3A4-2F1E70D423B6Q28487653-2ED43E30-2D1C-4060-936A-C9B4223AD3BAQ30404353-80D82177-6742-40ED-A93D-DCB66393D72EQ33774225-BD9F1313-E7EE-4ACC-B82C-417E4738C303Q33977578-D50CBBB3-C8B0-4ED8-9068-D791ABA5BB54Q33979304-F845D61D-1342-4C6F-8B7C-50A3682ECF51Q33981387-7C38EABE-5F33-4BCA-A51B-797A21D32559Q34108880-D0FB052F-654D-4FED-8CDA-8CBEFF47F210Q34352100-AF441AB7-F253-4C10-B3AC-8B24709C0B0BQ34932922-2B8673AA-E7A9-4E46-AACB-73B3ABB93940Q35718542-F78242C0-2570-4466-B45C-E3C429D7B45BQ35806170-512749B4-5981-4FB8-A051-E0D73921E6E6Q37162258-C6F34BB8-22AD-40E1-AE1E-8BC480B08544Q41849134-03326B0E-B969-40E0-87B7-A185F7B9B1D4Q41912237-8982B1D1-437B-401E-BEFD-0E1AD6BFDA6E
P2860
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
@ast
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
@en
type
label
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
@ast
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
@en
prefLabel
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
@ast
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
@en
P2093
P2860
P1476
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
@en
P2093
M A Pfaller
M E Klepser
S A Messer
P2860
P304
P407
P577
1998-06-01T00:00:00Z